Pacific Shuanglin Bio pharmacy Co Ltd (000403) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Pacific Shuanglin Bio pharmacy Co Ltd stock ¥6.54, price ¥9.72, that is 32.8% below the price, quality 31 out of 100. Rating: overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.
How to read this chart
60‑month range ¥8.65 – ¥27.77 · fair‑value band ¥5.38 – ¥8.50 · the ¥9.72 price screens above the ¥6.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.
Follow Pacific Shuanglin Bio pharmacy Co in your weekly email
Every Wednesday you see whether Pacific Shuanglin Bio pharmacy Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally.
Show moreShow less
The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen, lyophilized intravenous immunoglobulin (pH4), hepatitis B immunoglobulin (pH4), and human prothrombin complex concentrate, as well as intravenous cytomegalovirus immunoglobulin and intravenous respiratory syncytial virus immunoglobulin.
It is also involved in blood acquisition; plasma collection; consulting; trading; investment activities; and technology promotion and application services.
The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is headquartered in Taiyuan, China.
Stock analysis
Pacific Shuanglin Bio pharmacy Co Ltd (000403) currently trades at ¥9.72, while our model-based Fair Value estimate is ¥6.54, 33% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥10.47 per share, and 4 of the 16 models we run sit above the ¥9.72 price.
Bear case: the Asset-Based group reads lowest at ¥2.46, and 12 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥5.38 (bear) to ¥8.50 (bull), the price of ¥9.72 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Pacific Shuanglin Bio pharmacy Co Ltd reported revenue of 2.6B CNY in FY2025 versus 2.0B CNY in FY2021, a compound +7.5%/yr. Reported net income was 419M CNY in FY2025, compounding +1.8%/yr from FY2021.
Key figures
Market cap 9.2B CNY (≈ $1.4B) Small · P/E ratio 46.3 · P/S ratio 3.82 · EPS (TTM) ¥0.2100 · Dividend yield 1.5% · Net margin 8.8% · Return on equity 2.7% · Return on assets (EBIT) 7.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 39% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −33%, 000403 screens richer than that median.
Fair Value models
Bear¥5.38Fair Value ¥6.54Bull¥8.50
Price ¥9.72 · Downside -32.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.0513 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income¥6.33¥6.39¥6.7176
EPV¥4.83¥5.44¥5.9574
ROIC Compounder¥4.83¥5.44¥5.9572
All 16 models by family
Earnings-Based
Graham-Dodd¥3.00¥11.98¥16.2964
Lynch FV¥2.98¥4.25¥5.5361
PEG = 1.0¥2.98¥4.25¥5.5357
EPV¥4.83¥5.44¥5.9574
Dividend Discount
Gordon GGM¥2.34¥4.37¥6.2167
DDM Multi-Stage¥2.34¥3.92¥4.6567
Multiples
P/E Multiple¥7.28¥9.71¥12.1363
P/S Multiple¥5.62¥7.50¥9.3758
P/B Multiple¥18.41¥24.54¥30.6855
EV/EBIT¥8.59¥11.22¥13.8466
EV/EBITDA¥8.78¥11.46¥14.1467
EV/Revenue¥6.34¥8.75¥11.1554
Asset-Based
NCAV (Graham)¥1.63¥2.46¥3.0855
Economic Profit
Residual Income¥6.33¥6.39¥6.7176
ROIC Compounder¥4.83¥5.44¥5.9572
Growth Earnings
Growth-Adj P/E¥5.38¥7.69¥10.0067
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.2%
Start year 2020 (pandemic). Over 10 years: +18.1% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+4.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.1%
Dividend (yield on the price)1.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3.1% vs 11.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 22%
Compare Pacific Shuanglin Bio pharmacy Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−32.8% · Above median
Profitability
Return on equity (12 months)2.7% · Above median
Return on assets4.4% · Top 25%
Net margin (12 months)8.8% · Above median
Operating margin (12 months)11.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)−9.2% · Below median
Dividend yield (12 months)1.5% · Above median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)46.3× · Pricier than median
P/B1.14× · Cheaper than median
P/S (12 months)3.82× · Cheaper than median
EV/EBITDA18.8× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)11· sector 0
HEALTH (low debt)99· sector 97
DIVIDEND (yield)31· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pacific Shuanglin Bio pharmacy Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/000403
Frequently asked questions
Is Pacific Shuanglin Bio pharmacy Co Ltd (000403) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of ¥6.54 versus a price of ¥9.72, about 33% lower (overvalued).
What is the fair value of 000403?
Our model-based fair value for Pacific Shuanglin Bio pharmacy Co Ltd is ¥6.54 (as of Nov 2, 2026), built from audited fundamentals. The current price: ¥9.72.
What is the quality score of 000403?
Pacific Shuanglin Bio pharmacy Co Ltd has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
Our model-based price target is the fair value of ¥6.54 (as of Nov 2, 2026) from 16 valuation models. Cautious scenario ¥5.38, optimistic scenario ¥8.50. It is a calculation from audited fundamentals, not an analyst target.
What is the Pacific Shuanglin Bio pharmacy Co Ltd stock forecast for 2026?
Our models put fair value at ¥6.54, about 33% lower versus a price of ¥9.72 (overvalued). Cautious scenario ¥5.38, optimistic scenario ¥8.50. The calculation is refreshed regularly with new filings.
What is the revenue of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
Pacific Shuanglin Bio pharmacy Co Ltd reported trailing-twelve-month revenue of about 2.4B CNY (latest available figure, as of Nov 2, 2026).
Does Pacific Shuanglin Bio pharmacy Co Ltd pay a dividend?
Pacific Shuanglin Bio pharmacy Co Ltd currently shows a dividend yield of 1.54% relative to its recent price (as of Nov 2, 2026).
How much is the dividend of Pacific Shuanglin Bio pharmacy Co Ltd (000403) and when is the ex-dividend date?
Pacific Shuanglin Bio pharmacy Co Ltd pays a dividend of ¥0.15 per share a year, a dividend yield of 1.5%. The last ex-dividend date was Oct 23, 2026. A dividend has been paid every year since 2022. The payout ratio is 71.4% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pacific Shuanglin Bio pharmacy Co Ltd it is ¥6.54 per share (as of Nov 2, 2026), against a price of ¥9.72. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Pacific Shuanglin Bio pharmacy Co Ltd stock overvalued or undervalued in 2026?
As of Nov 2, 2026, 000403 trades above its calculated fair value: price ¥9.72, fair value ¥6.54, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000403?
No. The price is what the market pays today (¥9.72); the fair value is what the company's own numbers justify (¥6.54). For Pacific Shuanglin Bio pharmacy Co Ltd the two are ¥3.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pacific Shuanglin Bio pharmacy Co Ltd worth?
The market values Pacific Shuanglin Bio pharmacy Co Ltd at about 9.2B CNY (market capitalisation, as of Nov 2, 2026). Per share that is ¥9.72; our models calculate a fair value of ¥6.54 per share.
What do the bullish and bearish scenarios say about 000403?
Our models span a range for Pacific Shuanglin Bio pharmacy Co Ltd: cautious scenario ¥5.38, base ¥6.54, optimistic ¥8.50 per share (as of Nov 2, 2026, price ¥9.72). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 000403?
Pacific Shuanglin Bio pharmacy Co Ltd trades at a price-to-earnings ratio of 46.3 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥6.54 is built from several models across several years. Other multiples: P/B 1.1, P/S 3.8, EV/EBITDA 18.8.
How solid is the balance sheet of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
Balance-sheet figures for Pacific Shuanglin Bio pharmacy Co Ltd (as of Nov 2, 2026): return on equity 2.7%, debt of 0.02 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 000403 from its 52-week high?
Pacific Shuanglin Bio pharmacy Co Ltd trades at ¥9.72, about 39% below its 52-week high of ¥16.06 and 12% above the low of ¥8.65 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥6.54 is for.
Which stocks are comparable to Pacific Shuanglin Bio pharmacy Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pacific Shuanglin Bio pharmacy Co Ltd stock attractive at the current price?
The data as of Nov 2, 2026: price ¥9.72, calculated fair value ¥6.54 (−33%), Quality Score 31/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000403 calculated?
We run Pacific Shuanglin Bio pharmacy Co Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥6.54 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Pacific Shuanglin Bio pharmacy Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
The closing price on Nov 6, 2026 was ¥9.72. Our model-based fair value is ¥6.54, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pacific Shuanglin Bio pharmacy Co Ltd right now?
The price sits above even our optimistic bull case (¥8.50). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts.
Where does the earnings growth of Pacific Shuanglin Bio pharmacy Co Ltd (000403) come from?
Earnings per share at Pacific Shuanglin Bio pharmacy Co Ltd grew +20.2 % a year from 2013 to 2024. Broken into its drivers: revenue per share +15.6 %, EBIT margin +7.7 %, tax rate +1.9 %, residual (interest, one-offs) −5.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Pacific Shuanglin Bio pharmacy Co Ltd
How large is the market capitalisation of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
The market capitalisation of Pacific Shuanglin Bio pharmacy Co Ltd is 9.2B CNY (≈ $1.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
The price-to-sales ratio of Pacific Shuanglin Bio pharmacy Co Ltd is 3.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
Earnings per share at Pacific Shuanglin Bio pharmacy Co Ltd are ¥0.2100 (price ÷ EPS = P/E 46.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
The dividend yield of Pacific Shuanglin Bio pharmacy Co Ltd is 1.5% (payout 71.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
The net margin of Pacific Shuanglin Bio pharmacy Co Ltd is 8.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
The return on equity (ROE) of Pacific Shuanglin Bio pharmacy Co Ltd is 2.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
On an EBIT basis the return on assets of Pacific Shuanglin Bio pharmacy Co Ltd is 7.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
The operating margin of Pacific Shuanglin Bio pharmacy Co Ltd is 11.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
Revenue at Pacific Shuanglin Bio pharmacy Co Ltd is growing −9.2% versus a year earlier (3y avg +3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pacific Shuanglin Bio pharmacy Co Ltd (000403)?
Earnings per share at Pacific Shuanglin Bio pharmacy Co Ltd are growing −46.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Pacific Shuanglin Bio pharmacy Co Ltd (000403) generate?
The free cash flow of Pacific Shuanglin Bio pharmacy Co Ltd is −549M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Pacific Shuanglin Bio pharmacy Co Ltd (000403) hold?
Pacific Shuanglin Bio pharmacy Co Ltd holds more cash than debt, 689M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Pacific Shuanglin Bio pharmacy Co Ltd in the live analysis
One click puts Pacific Shuanglin Bio pharmacy Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 2, 2026